XBiotech Inc.XBITEarnings & Financial Report
XBiotech Inc. is a clinical-stage biopharmaceutical company based in Austin, Texas. It specializes in the research and development of human-derived antibody therapeutics for multiple diseases, including cancer, rheumatological, and infectious diseases.
XBIT Q4 FY2023 Key Financial Metrics
Revenue
$0
Gross Profit
$0
Operating Profit
$-8.6M
Net Profit
$-4.6M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.15
XBiotech Inc. Q4 FY2023 Financial Summary
XBiotech Inc. reported revenue of $0 for Q4 FY2023, with a net profit of $-4.6M (down 44.7% YoY) (N/A margin). Cost of goods sold was $0, operating expenses totaled $8.6M.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-4.6M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 FY2023 |
XBiotech Inc. Annual Revenue by Year
XBiotech Inc. annual revenue history includes year-by-year totals (for example, 2023 revenue was $0).
XBiotech Inc. Quarterly Revenue & Net Profit History
XBiotech Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2023 | $0 | — | $-4.6M | N/A |
| Q3 FY2023 | $0 | — | $-7.4M | N/A |
| Q2 FY2023 | $0 | — | $-8.7M | N/A |
| Q1 FY2023 | $0 | — | $-3.8M | N/A |
| Q4 FY2022 | $300.0K | -93.3% | $-3.2M | -1067.7% |
| Q3 FY2022 | $1.7M | -62.8% | $-12.7M | -753.5% |
| Q2 FY2022 | $1.5M | -66.2% | $-11.6M | -761.0% |
| Q1 FY2022 | $500.0K | -89.7% | $-5.4M | -1079.0% |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $500000 | $1.5M | $1.7M | $300000 | $0 | $0 | $0 | $0 |
| YoY Growth | -89.7% | -66.2% | -62.8% | -93.3% | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $270.8M | $266.5M | $250.8M | $246.1M | $242.1M | $235.1M | $229.6M | $226.6M |
| Liabilities | $5.2M | $10.7M | $6.0M | $5.7M | $5.2M | $6.1M | $6.9M | $7.8M |
| Equity | $265.6M | $255.8M | $244.8M | $240.4M | $236.9M | $229.1M | $222.7M | $218.8M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-5.1M | $-5.4M | $-1.1M | $-3.2M | $-4.8M | $-9.0M | $-1.5M | $-3.4M |